Laboratory Test in Predicting Response to Erlotinib in Patients With Relapsed Metastatic or Unresectable Non-Small Cell Lung Cancer That Did Not Respond to Previous Treatment

NCT00673569 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: erlotinib hydrochloride
GENETIC: gene expression analysis
GENETIC: protein expression analysis
OTHER: immunoenzyme technique
OTHER: immunologic technique
OTHER: laboratory biomarker analysis
PROCEDURE: needle biopsy

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]